Healthcare Services

Global Myelofibrosis (MF) Market Expected to Reach $1.79 Billion by 2030 with 3% CAGR

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Myelofibrosis (MF) Market During The Forecast Period 2026–2030?

The myelofibrosis (mf) market size has demonstrated steady expansion in recent years. It is forecast to grow from $1.55 billion in 2025 to $1.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.2%. This historical growth can be attributed to several factors, including the limited treatment options accessible, the high prevalence of anemia among mf patients, an increase in autoimmune-related conditions, elevated diagnostic complexities, and a reliance on corticosteroid-based management.

The myelofibrosis (mf) market size is projected to experience consistent expansion over the upcoming years, reaching $1.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.0%. This anticipated growth during the forecast period is driven by progress in JAK inhibitor development, wider acceptance of precision medicine, greater investment in hematology research and development, evolving stem-cell therapy advancements, and an increasing availability of targeted oral therapies. Key trends expected in this period encompass the rising uptake of JAK inhibitor-based treatments, a heightened focus on combination therapy strategies, an increased emphasis on early detection and screening initiatives, expanding studies in stem-cell transplantation and regenerative care, and enhanced utilization of supportive care to alleviate symptom burden.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21226&type=smp

Which Major Factors Are Driving The Expansion Of The Myelofibrosis (MF) Market?

The myelofibrosis (MF) market is expected to grow due to the increasing need for targeted therapies. Targeted therapies are a medical strategy that customizes treatments and healthcare decisions based on individual genetic, environmental, and lifestyle attributes. This rising demand for targeted therapies is fueled by advancements in genomics, biotechnology, and data analytics, allowing for more precise, effective, and individualized treatment approaches. Myelofibrosis (MF) offers a vital framework for the creation of targeted therapies by identifying crucial molecular pathways, such as JAK-STAT signaling. This enables the development of precision treatments like JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) designed to manage symptoms and slow the progression of the disease. For instance, in May 2024, the American Cancer Society, a US-based non-profit organization, estimated approximately 81,610 new kidney cancer cases (52,380 men and 29,230 women) are anticipated in the United States in 2024, along with an estimated 14,390 deaths (9,450 men and 4,940 women). Consequently, the growing demand for targeted therapies is a key driver for the myelofibrosis (MF) market’s expansion.

What Market Segments Are Evaluated Within The Myelofibrosis (MF) Market?

The myelofibrosis (mf) market covered in this report is segmented –

1) By Drug Type: Jak Inhibitor, Immunomodulators, Hydroxyurea, Other Drug Types

2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Jak Inhibitor: Ruxolitinib, Fedratinib, Momelotinib, Itacitinib

2) By Immunomodulators: Thalidomide, Lenalidomide, Pomalidomide

3) By Hydroxyurea: Oral Hydroxyurea, Injectable Hydroxyurea

4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs), Danazol, Monoclonal Antibodies, Chemotherapy Agents

Which Trends Are Impacting The Growth Of The Myelofibrosis (MF) Market?

Major companies engaged in the myelofibrosis (MF) market are concentrating on expanding targeted therapies, such as JAK1/JAK2 and ACVR1 inhibitors, to boost treatment effectiveness, manage disease progression, and enhance patient outcomes in myelofibrosis (MF). JAK1/JAK2 inhibitors specifically target the Janus kinase pathway to lessen inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors function by blocking activin receptor-like kinase 2 (ALK2) to control bone marrow fibrosis and disease advancement. For example, in September 2023, GSK plc, a UK-based pharmaceutical company, secured US Food and Drug Administration (FDA) approval for Ojjaara (momelotinib), indicated for treating intermediate- or high-risk myelofibrosis. Its dual action mechanism, which targets both JAK1/JAK2 and ACVR1, aids in regulating inflammatory pathways and simultaneously improving hemoglobin levels, consequently reducing the necessity for transfusions. This approval not only broadens treatment possibilities but also establishes a new benchmark in MF management for patients suffering from anemia, a significant unaddressed requirement in the disease landscape.

Who Are The Top Market Participants Influencing The Myelofibrosis (MF) Market?

Major companies operating in the myelofibrosis (mf) market are Pfizer Inc, Novartis AG, Incyte Corporation, CTI BioPharma Corp, Karyopharm Therapeutics Inc, Sierra Oncology Inc, Kartos Therapeutics Inc, NS Pharma Inc, Keros Therapeutics Inc, Pharmaxis Ltd, Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, AbbVie Inc, Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Taiga Biotechnologies Inc, Rigel Pharmaceuticals Inc, Imago BioSciences Inc, Samus Therapeutics Inc.

Read the full myelofibrosis (mf) market report here:

https://www.thebusinessresearchcompany.com/report/myelofibrosis-mf-global-market-report

Which Region Currently Holds The Largest Share Of The Myelofibrosis (MF) Market?

North America was the largest region in the myelofibrosis (MF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myelofibrosis (mf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Myelofibrosis (MF) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21226&type=smp

Browse Through More Reports Similar to the Global Myelofibrosis (MF) Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myelodysplastic Syndrome Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795